CA2511013A1 - Agonistes multivalents de recepteur beta de lymphotoxine et leurs applications therapeutiques - Google Patents
Agonistes multivalents de recepteur beta de lymphotoxine et leurs applications therapeutiques Download PDFInfo
- Publication number
- CA2511013A1 CA2511013A1 CA002511013A CA2511013A CA2511013A1 CA 2511013 A1 CA2511013 A1 CA 2511013A1 CA 002511013 A CA002511013 A CA 002511013A CA 2511013 A CA2511013 A CA 2511013A CA 2511013 A1 CA2511013 A1 CA 2511013A1
- Authority
- CA
- Canada
- Prior art keywords
- ser
- antibody
- val
- thr
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne des structures d'anticorps multivalents spécifiques au récepteur bêta de lymphotoxine humaine ainsi que leur utilisation dans le traitement du cancer et l'inhibition de l'augmentation du volume des tumeurs chez un sujet.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43515402P | 2002-12-20 | 2002-12-20 | |
US60/435,154 | 2002-12-20 | ||
PCT/US2003/041393 WO2004058191A2 (fr) | 2002-12-20 | 2003-12-22 | Agonistes multivalents de recepteur beta de lymphotoxine et leurs applications therapeutiques |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2511013A1 true CA2511013A1 (fr) | 2004-07-15 |
Family
ID=32682169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002511013A Abandoned CA2511013A1 (fr) | 2002-12-20 | 2003-12-22 | Agonistes multivalents de recepteur beta de lymphotoxine et leurs applications therapeutiques |
Country Status (8)
Country | Link |
---|---|
US (1) | US20060104971A1 (fr) |
EP (1) | EP1583503A4 (fr) |
JP (1) | JP2006515750A (fr) |
CN (1) | CN100473664C (fr) |
AU (1) | AU2003299984A1 (fr) |
CA (1) | CA2511013A1 (fr) |
NO (1) | NO20053530L (fr) |
WO (1) | WO2004058191A2 (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6312691B1 (en) * | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
US5925351A (en) | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
GEP20063752B (en) * | 2000-10-13 | 2006-02-27 | Biogen Inc | Humanized Anti-LT-Beta-R Antibodies |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2004002431A2 (fr) * | 2002-07-01 | 2004-01-08 | Biogen, Inc. | Anticorps humanises diriges contre le recepteur de la lymphotoxine beta |
WO2004003144A2 (fr) | 2002-07-01 | 2004-01-08 | Human Genome Sciences, Inc. | Anticorps qui se lient specifiquement a reg iv |
MXPA05006663A (es) * | 2002-12-20 | 2005-09-30 | Biogen Idec Inc | Agentes del receptor linfotoxina beta en combinacion con agentes quimioterapeuticos. |
WO2005000898A2 (fr) * | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Purification et synthese preferentielle de molecules de liaison |
CA2560742A1 (fr) * | 2004-03-23 | 2005-10-06 | Biogen Idec Ma Inc. | Agents de couplage recepteurs et leurs applications therapeutiques |
WO2006074399A2 (fr) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Molecules de liaison multispecifiques comprenant des peptides de connexion |
HUE026303T2 (hu) | 2005-07-25 | 2016-06-28 | Emergent Product Dev Seattle | B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával |
AU2007227292B2 (en) | 2006-03-17 | 2012-04-12 | Biogen Ma Inc. | Stabilized polypeptide compositions |
AU2014200661B2 (en) * | 2006-06-12 | 2016-06-30 | Aptevo Research And Development Llc | Single-chain multivalent binding proteins with effector function |
AU2016231617B2 (en) * | 2006-06-12 | 2018-08-23 | Aptevo Research And Development Llc | Single-chain multivalent binding proteins with effector function |
EP2418223A3 (fr) * | 2006-06-12 | 2013-01-16 | Emergent Product Development Seattle, LLC | Protéines de liaison polyvalente à chaîne unique avec une fonction effectrice |
US8338376B2 (en) * | 2006-10-20 | 2012-12-25 | Biogen Idec Ma Inc. | Compositions comprising variant LT-B-R-IG fusion proteins |
SG154441A1 (en) * | 2006-10-20 | 2009-08-28 | Biogen Idec Inc | Treatment of demyelinating disorders |
BRPI0814060A2 (pt) * | 2007-07-06 | 2015-01-06 | Trubion Pharmaceuticals Inc | Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal |
AU2008282218A1 (en) * | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
KR100967623B1 (ko) * | 2008-02-22 | 2010-07-05 | 전남대학교산학협력단 | 림포톡신을 포함하는 자궁경부암 예방 또는 치료용 조성물 |
DK2132228T3 (da) | 2008-04-11 | 2011-10-10 | Emergent Product Dev Seattle | CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf |
JP6211597B2 (ja) * | 2012-05-01 | 2017-10-11 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | 新規抗体 |
EP2950788B1 (fr) * | 2013-02-04 | 2019-01-09 | University Of Huddersfield | Composition comprenant un agoniste de tnfr et au moins un inhibiteur de thiorédoxine destiné à être utilisé dans le traitement d'un carcinome |
TWI700295B (zh) | 2013-12-16 | 2020-08-01 | 馬來西亞商Mab探索私人有限公司 | 對會感染人類之腸病毒具有專一性之抗體 |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
CN108367004B (zh) | 2015-09-21 | 2022-09-13 | 阿帕特夫研究和发展有限公司 | Cd3结合多肽 |
WO2017062604A1 (fr) | 2015-10-06 | 2017-04-13 | Regents Of The University Of Minnesota | Composés thérapeutiques et procédés |
US20240018248A1 (en) | 2020-12-02 | 2024-01-18 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
WO2022117569A1 (fr) | 2020-12-02 | 2022-06-09 | Oncurious Nv | Anticorps antagoniste de ccr8 en combinaison avec un anticorps agoniste du récepteur bêta de la lymphotoxine en thérapie contre le cancer |
WO2023198848A1 (fr) | 2022-04-13 | 2023-10-19 | Vib Vzw | Agoniste de ltbr utilisé en polythérapie contre le cancer |
WO2023218320A1 (fr) * | 2022-05-11 | 2023-11-16 | Pfizer Inc. | Anticorps anti-récepteur de la lymphotoxine bêta et leurs procédés d'utilisation |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US669941A (en) * | 1898-12-17 | 1901-03-12 | Electric Axle Light & Power Company | Electric switch. |
US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
ATE397665T1 (de) * | 1992-12-04 | 2008-06-15 | Biogen Idec Inc | Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon |
US6312691B1 (en) * | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
EP0809510B1 (fr) * | 1995-01-26 | 2004-06-09 | Biogen, Inc. | Complexes de lymphotoxine-alpha/beta et anticorps de recepteur anti-lymphotoxine-beta utiles en tant qu'agents anti-tumoraux |
US5925351A (en) * | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
US7060667B1 (en) * | 1998-01-30 | 2006-06-13 | Biogen Idec Ma, Inc. | Treatment of follicular lymphomas using inhibitors of the LT pathway |
TR200504220T2 (tr) * | 1998-12-17 | 2007-04-24 | Biogen Idec Ma Inc. | Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem. |
EP1272647B1 (fr) * | 2000-04-11 | 2014-11-12 | Genentech, Inc. | Anticorps multivalents et leurs utilisations |
AU7967801A (en) * | 2000-06-30 | 2002-01-14 | Innogenetics Nv | Differential diagnosis of neurological diseases |
JP2004520810A (ja) * | 2000-08-24 | 2004-07-15 | ジェネンテック・インコーポレーテッド | 腫瘍の診断と治療のための組成物と方法 |
GEP20063752B (en) * | 2000-10-13 | 2006-02-27 | Biogen Inc | Humanized Anti-LT-Beta-R Antibodies |
US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7642242B2 (en) * | 2002-03-05 | 2010-01-05 | Genentech, Inc. | PRO34128 polypeptides |
WO2004002431A2 (fr) * | 2002-07-01 | 2004-01-08 | Biogen, Inc. | Anticorps humanises diriges contre le recepteur de la lymphotoxine beta |
MXPA05006663A (es) * | 2002-12-20 | 2005-09-30 | Biogen Idec Inc | Agentes del receptor linfotoxina beta en combinacion con agentes quimioterapeuticos. |
-
2003
- 2003-12-22 JP JP2004562588A patent/JP2006515750A/ja active Pending
- 2003-12-22 WO PCT/US2003/041393 patent/WO2004058191A2/fr active Search and Examination
- 2003-12-22 CN CNB2003801090429A patent/CN100473664C/zh not_active Expired - Fee Related
- 2003-12-22 CA CA002511013A patent/CA2511013A1/fr not_active Abandoned
- 2003-12-22 AU AU2003299984A patent/AU2003299984A1/en not_active Abandoned
- 2003-12-22 EP EP03800249A patent/EP1583503A4/fr not_active Withdrawn
-
2005
- 2005-06-17 US US11/155,444 patent/US20060104971A1/en not_active Abandoned
- 2005-07-19 NO NO20053530A patent/NO20053530L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2004058191A3 (fr) | 2005-12-29 |
CN1798765A (zh) | 2006-07-05 |
JP2006515750A (ja) | 2006-06-08 |
AU2003299984A1 (en) | 2004-07-22 |
CN100473664C (zh) | 2009-04-01 |
NO20053530D0 (no) | 2005-07-19 |
US20060104971A1 (en) | 2006-05-18 |
NO20053530L (no) | 2005-09-20 |
EP1583503A4 (fr) | 2006-08-09 |
WO2004058191A2 (fr) | 2004-07-15 |
EP1583503A2 (fr) | 2005-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2511013A1 (fr) | Agonistes multivalents de recepteur beta de lymphotoxine et leurs applications therapeutiques | |
AU2020203365B2 (en) | CD33 antibodies and use of same to treat cancer | |
RU2755503C2 (ru) | Анти-lag-3 антитела и их композиции | |
CN107922496B (zh) | IL2Rβ/通用γ链抗体 | |
KR20220110224A (ko) | Bcma에 결합하는 항체 및 이의 용도 | |
KR20060132006A (ko) | 수용체 커플링제 및 이의 치료적 용도 | |
EP2021370B1 (fr) | Agents de liaison du récepteur trail et leurs utilisations | |
CN110799540B (zh) | 多特异性抗体及其制备和使用方法 | |
KR20050094819A (ko) | 화학요법제와 조합된 림프독소 베타 수용체 약제 | |
CN110831973B (zh) | 多特异性抗体及其制备和使用方法 | |
KR20160044043A (ko) | Gitr 항원 결합 단백질 | |
JP2006515750A5 (fr) | ||
CN110396129B (zh) | 人源化cd19抗原结合单链抗体及其嵌合抗原受体、免疫细胞和应用 | |
EP2074148A1 (fr) | Nouveaux anticorps anti-prolifération | |
CN114685660A (zh) | 抗cldn18.2抗体及其制备方法和应用 | |
KR20170082495A (ko) | 암 치료용 항-ck8 항체 | |
CN106795223A (zh) | 针对Fcγ受体IIB及Fcε受体的新型抗体 | |
KR20200123169A (ko) | B7-h4 항체 투약 섭생법 | |
KR20220160555A (ko) | Cd40에 결합하는 항체 및 이의 용도 | |
KR20160131082A (ko) | Lg1-3에 특이적인 항-라미닌4 항체 | |
KR20200108870A (ko) | Tim3에 대한 항체 및 그의 용도 | |
CN112175087B (zh) | 一种抗CD4和TGFβ的双特异性抗体、其药物组合及其用途 | |
RU2761638C1 (ru) | Антитела против лиганда программируемой смерти (pd-l1) и их применение | |
AU2021403263A1 (en) | Bispecific antibody for specifically neutralizing tgf-β signal of helper t cell, and pharmaceutical combination and use thereof | |
RU2811477C2 (ru) | Мультиспецифические антитела и способы их получения и применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |